Next Article in Journal
Use of Double-Layer Carotid Stents Is Associated with Improved Patient Survival and Lower Neurological Complications: A Single-Center Retrospective Observational Study
Next Article in Special Issue
Statin Use and Major Adverse Cardiovascular Events Among Patients with Ischemic Heart Diseases: A Multi-Center Retrospective Study
Previous Article in Journal
A Review and Comparison of Immune-Checkpoint Inhibitors in the Treatment of Metastatic Uveal Melanoma
Previous Article in Special Issue
Clinical Expression of Familial Hypercholesterolemia in Patients from France and French Canada Carrying Identical-by-Descent Pathogenic LDLR Gene Variants: A Proof-of-Concept Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 3
10.3390/jcm14030887
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Nanotechnology and Artificial Intelligence in Dyslipidemia Management—Cardiovascular Disease: Advances, Challenges, and Future Perspectives

by
Ewelina Młynarska
1,*,
Kinga Bojdo
1,†,
Hanna Frankenstein
1,†,
Natalia Kustosik
1,†,
Weronika Mstowska
1,†,
Aleksandra Przybylak
1,†,
Jacek Rysz
2 and
Beata Franczyk
1
1
Department of Nephrocardiology, Medical University of Lodz, 90-549 Łódź, Poland
2
Department of Nephrology, Hypertension and Internal Medicine, Medical University of Lodz, 90-549 Łodz, Poland
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2025, 14(3), 887; https://doi.org/10.3390/jcm14030887
Submission received: 16 December 2024 / Revised: 11 January 2025 / Accepted: 27 January 2025 / Published: 29 January 2025
(This article belongs to the Special Issue Management of Dyslipidaemias: Enhancing Lipid Modification to Reduce Cardiovascular Risk)
Browse Figures
Versions Notes

Abstract

This narrative review explores emerging technologies in dyslipidemia management, focusing on nanotechnology and artificial intelligence (AI). It examines the current treatment recommendations and contrasts them with the future prospects enabled by these innovations. Nanotechnology shows significant potential in enhancing drug delivery systems, enabling more targeted and efficient lipid-lowering therapies. In parallel, AI offers advancements in diagnostics, cardiovascular risk prediction, and personalized treatment strategies. AI-based decision support systems and machine learning algorithms are particularly promising for analyzing large datasets and delivering evidence-based recommendations. Together, these technologies hold the potential to revolutionize dyslipidemia management, improving outcomes and optimizing patient care. In addition, this review covers key topics such as cardiovascular disease biomarkers and risk factors, providing insights into the current methods for assessing cardiovascular risk. It also discusses the current understanding of dyslipidemia, including pathophysiology and clinical management. Together, these insights and technologies hold the potential to revolutionize dyslipidemia management, improving outcomes and optimizing patient care.
Keywords: dyslipidemia; cardiovascular disease; emerging lipid-lowering therapies; nanotechnology; artificial intelligence; cardiovascular risk-related biomarkers dyslipidemia; cardiovascular disease; emerging lipid-lowering therapies; nanotechnology; artificial intelligence; cardiovascular risk-related biomarkers

Share and Cite

MDPI and ACS Style

Młynarska, E.; Bojdo, K.; Frankenstein, H.; Kustosik, N.; Mstowska, W.; Przybylak, A.; Rysz, J.; Franczyk, B. Nanotechnology and Artificial Intelligence in Dyslipidemia Management—Cardiovascular Disease: Advances, Challenges, and Future Perspectives. J. Clin. Med. 2025, 14, 887. https://doi.org/10.3390/jcm14030887

AMA Style

Młynarska E, Bojdo K, Frankenstein H, Kustosik N, Mstowska W, Przybylak A, Rysz J, Franczyk B. Nanotechnology and Artificial Intelligence in Dyslipidemia Management—Cardiovascular Disease: Advances, Challenges, and Future Perspectives. Journal of Clinical Medicine. 2025; 14(3):887. https://doi.org/10.3390/jcm14030887

Chicago/Turabian Style

Młynarska, Ewelina, Kinga Bojdo, Hanna Frankenstein, Natalia Kustosik, Weronika Mstowska, Aleksandra Przybylak, Jacek Rysz, and Beata Franczyk. 2025. "Nanotechnology and Artificial Intelligence in Dyslipidemia Management—Cardiovascular Disease: Advances, Challenges, and Future Perspectives" Journal of Clinical Medicine 14, no. 3: 887. https://doi.org/10.3390/jcm14030887

APA Style

Młynarska, E., Bojdo, K., Frankenstein, H., Kustosik, N., Mstowska, W., Przybylak, A., Rysz, J., & Franczyk, B. (2025). Nanotechnology and Artificial Intelligence in Dyslipidemia Management—Cardiovascular Disease: Advances, Challenges, and Future Perspectives. Journal of Clinical Medicine, 14(3), 887. https://doi.org/10.3390/jcm14030887

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop